CSI Market
Sign In | Register

Tg Therapeutics Inc (TGTX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access TGTX quarterly Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Tg Therapeutics Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-447.18
Depreciation & amortization0.06
Amortization of Other Assets1.22
Increase (Decrease) in Deferred Revenue6.39
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-27.28
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation64.67
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Shares Issued In Connection With In Licensing Agreement-
Investment Income Amortization Of Premium-
Extinguishment Of Debt Gain Loss Net Of Tax-
Shares Issued In Connection With Inlicensing Agreement-
Noncash Licensing Expense-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Change In Fair Value of Notes Payable-
Amortization Of Leasehold Interest0.19
Operating Lease Right Of Use Asset Amortization Expense1.75
Equity Securities Fv Ni Unrealized Gain Loss0.30
Change In Fair Value Of Notes Payable0.03
Increase Decrease In Operating Lease Liability-3.79
Income taxes348.00
Gain (Loss) on Sale of Investments0.00
Increase (Decrease) in Accounts Receivable-176.44
Increase (Decrease) in Accounts Payable and Accrued Liabilities55.88
Increase (Decrease) in Other Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital-44.81
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities196.26
Discontinued operations0.00
Net Cash flow from Operating Activities-24.77
Investing Activities
Capital Expenditures-0.21
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities237.50
Payments to Acquire Held-to-maturity Securities-222.24
Real Estate Investments0.00
Investment In Heldtomaturity Shortterm Securities-
Payments To Acquire Held To Maturity Securities Long Term-
Payments To Acquire Held To Maturity Securities Short Term-
Proceeds From Maturities-
Payments To Acquire Equity Securities Fv Ni-1.25
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Long-term Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities13.80
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-89.73
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-261.68
Treasury Stock Value Acquired Cost Method-
Net Proceeds From Shares New Issues Overallotments-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents80.49
Repayment Of Offering Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations181.19
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-89.73
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-24.99
Total Cash Flow-100.70
4 historic quarters locked

Sign in to unlock the full Tg Therapeutics Inc cash flow history.

Sign In Create Free Account

About Tg Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001437749-26-006133

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License